ဝက်သိန် ကဝ်ဝိဒ်-၁၉

နူ ဝဳကဳပဳဒဳယာ
အ​ညွှန်း​သို့ ခုန်ကူးရန် ရှာဖွေရန် ခုန်ကူးမည်
ဗီုရုပ်ဝက်သိန် ကဝ်ဝိဒ်-၁၉ နူကဵု ဖရိဇြာ
ဗီုတိ မထ္ၜး ဍုင်မပဒတန် ဝက်သိန်ဂမၠိုင်
  Approved for general use, mass vaccination underway
  EUA granted, mass vaccination underway
  EUA granted, limited vaccination
  Approved for general use, mass vaccination planned
  EUA granted, mass vaccination planned
  EUA pending

ဝက်သိန် ကဝ်ဝိဒ်-၁၉ (အၚ်္ဂလိက်: COVID‑19 vaccine) ဂှ် ဒှ် ဝက်သိန် မပကဵု ညံင်ဒြဟတ်အိမ်မုန်မသ္ဂောအ်တီ သွက်ဂွံဒစဵုဒစး ယဲကဝ်ဝိဒ်-၁၉။ ကိုပ်ကၠာ ကပ်ယဲကဝ်ဝိဒ်-၁၉ ဟွံကတဵုဒှ်ဏီဂှ်ရ၊ တၠပညာတအ် ကၠောန်ပ္တိတ်လဝ် ဝက်သေန် သွက်ဂွံဗတိုက် ကဝ်ရဝ်နာဝဳရုသ် မပကဵု ညံင်ဂွံဒှ်ယဲသာ (SARS) ကေုာံ ယဲမာ (MERS)တုဲ တၠပညာတအ် တီကၠိုဟ်လဝ် ပရူလဒက်ပ္တန် ကေုာံ တၠုင်လအာ ကဝ်ရဝ်နာဝဳရုသ်ရ။ ကာလ ကဝ်ရဝ်နာဝဳရုသ်ဂကူတၞဟ် မပကဵု ညံင်ဂွံဒှ် ယဲကဝ်ဝိဒ်-၁၉ မကတဵုဒှ် ပ္ဍဲတမ်သၞာံ ၂၀၂၀ ဂှ် ညးတအ် စဂစာန်ကၠောန် ဝက်သိန်-ကဝ်ဝိဒ်-၁၉။

စိုပ်ၜိုတ် လဒေါဝ်ဒဳဇြေမ်ဗါ ၂၀၂၀ ဂှ် လၟောဝ်ဝက်သိန် ၅၇ ဂှ် ဂစာန်ကၠောန် ပဒၟံင်သုတေသနဂဥုဲတုဲ ပၞောဝ်တအ်ဂှ် ၄၀ ဂှ် နွံဒၟံင် ကဆံင်ကာလစွမ် ပထမ - ဒုတိယတုဲ ၁၇ ဂှ် နွံဒၟံင် ကဆံင်ကာလစွမ် ဒုတိယ - တတိယ။ ပ္ဍဲကဆံင်ကာလစွမ်တတိယဂှ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉ ဗွဲမဂၠိုင် ကၠောန်ကမၠောန် ၜိုတ် ၉၅% သွက်ဂွံစဵုဒၞာ ယဲကဝ်ဝိဒ်-၁၉။[၁] ဝက်သိန်လ္ၚဵုတအ်ဂှ် ဍုင်လ္ၚဵု ပဒတန်တုဲ ဝက်သိန်လ္ၚဵုတအ်ဂှ် ဍုင်လ္ၚဵု ဟွံပဒတန်ရ။ သီုဖအိုတ် မဂွံဒုင်ပဒတန် နကဵု အေဂျေန်သဳ ထတ်ယုက်ဍုင်တအ်ဂှ် နွံ မသုန် မပ္တံကဵု တဝ်ဇြဳနာမေရန် (Tozinameran) မကၠောန်ပ္တိတ် နူကဵု ဖြိဇြေရ်-ဗဳသြတေက် (Pfizer–BioNTech)၊ ဗဳဗဳဗ်-ကောဝ် (BBIBP-CorV) မကၠောန်ပ္တိတ် နူကဵု သဳနဝ်ဖာမ် (Sinopharm)၊ ကဝ်ရဝ်နာဝက် (CoronaVac) မကၠောန်ပ္တိတ် နူကဵု သဳနဝ်ဝက် (Sinovac)၊ အာမ်အာနာ-၁၂၇၃ (mRNA-1273) မကၠောန်ပ္တိတ် နူကဵု မဝ်ဒေရ်နာ (Moderna) ကေုာံ ဂမ်-ကဝ်ဝိဒ်-ဝက် (Gam-COVID-Vac) မကၠောန်ပ္တိတ် နူကဵု အေန်သတဳကျုတ်သုတေသနဂမလေယာ (Gamaleya Research Institute)။

ဖြိဇြေရ်၊ မဝ်ဒေရ်နာ ကေုာံ သြသတြဇြေနေက (AstraZeneca) တအ် ဟီုလဝ် ပ္ဍဲသၞာံ ၂၀၂၁ မ္ဂး ညးတအ် ကၠောန်ပ္တိတ် လၟိဟ် ၅.၃ ဗဳလဳယာန် သွုင် မာန်တုဲ ကလိဂွံ မၞိဟ်ၜိုတ် ၃ ဗဳလဳယာန်မာန် (မၞိဟ်မွဲမ္ဂး ဒးထ္ပက် ၂ သွုင်/တၞိင် သွက်ဂွံစဵုဒၞာ ကဝ်ဝိဒ်-၁၉)၊ ပ္ဍဲဂိတုဒဳဇြေမ်ဗါဂှ် နူကဵု ဍုင်နာနာတအ် ဗကန်လဝ် နူကဵုဌာနပ္တိတ်ဝက်သိန်တအ် လၟိဟ် ၁၀ ဗဳလဳယာန်ပြင်င်[၂] ကဝက်ပြင်င်ဂှ် ဍုင်ပိုန်ဒြပ်ဇၞော်မောဝ်တအ် ဗကန်လဝ်တုဲ ဟီုကဵုလၟိဟ်မၞိဟ်ဂၠးကဝ်မ္ဂး ဍုင်သေဋ္ဌဳတအ်ဂှ် လၟိဟ်မၞိဟ် နွံ ၁၄% ဓဝ်ရ။[၃] ဍုင်ဗွဲမဂၠိုင်တအ်ဂှ် ဖျေဟ်လၟေင်ကမၠောန် ထပက်ဝက်သိန် နကဵု မၞိဟ်ဗယု၊ ယဲဇမၠိင် မဒှ်မၞိဟ်အန္တရာယ်ဇၞော် ကုယဲကဝ်ဝိဒ်-၁၉ ကေုာံ အစာဂဥုဲ အစာသဝ်ဂှ် ကဵုထ္ပက်ကၠာရ။[၄]

လၟေင်ကမၠောန် ကေုာံ ဓလိုက်တမ်ရိုဟ်[ပလေဝ်ဒါန် | ပလေဝ်ဒါန် တမ်ကၞက်]

ပ္ဍဲမွဲဒမြိပ်သၞာံ ၂၀၂၀ နူစ သၞာံမံက်၊ ယဲကပ်စကတဵုဒှ်ဂှ် ဌာနမကၠောန်ပ္တိတ်ဂဥုဲဂမၠိုင်၊ အလဵုအသဳဍုင် ကေုာံ ကမ္မဏဳမဆေင်ကဵုဇဳဝဗေဒ နူကဵု ရးနိဂီုနာနာ ပ္တိတ်အာရီု ဂစာန်ကၠောန်ကၠုင် သွက်ကလိဂွံ ဝက်သိန်ကဝ်ဝိဒ်-၁၉ အိုတ်ရ။[၅] အတိုင် ဂကောံပံင်ကောံမခၞံဗဒှ်သွက်စဵုဒၞာကပ်ယဲ (Coalition for Epidemic Preparedness Innovations -CEPI) မဗမံက်ထ္ၜးလဝ်မ္ဂး ဂကောံမပါလုပ် ပ္ဍဲအရာမကၠောန်ပ္တိတ် ဝက်သိန်ဏအ်ဂှ် နူကဵု အမေရိသၟဝ်ကျာဂှ် ၜိုတ် ၄၀%၊ အာရှ ကဵု အဝ်သတြေလျာ ၃၀%၊ ဥရောပ ၂၆% တုဲ ပ္ဍဲအမေရိသၠုင်ကျာ ကဵု အာဖရိကဂှ် ပါလုပ်ညိညကီုရ။[၅][၆]

လၟောဝ်ဝက်သိန်မွဲမွဲ ဂွံကလိဂွံဇမၞးမာန်ဂှ် ဒးအိုတ်သြန် ဗွဲမဂၠိုင်ဂၠေင်ရ။ ဥပမာ ခရိတ်င္ၚုဟ်အိုတ် ပ္ဍဲ ကာလစွမ်မၞိဟ်အလန်ပထမဂှ်သၟးဂှ် ဒးအိုတ် သြန်ဒဝ်လာအမေရိကာန် အကြာ ၁၄ မဳလဳယာန်ကဵု ၂၅ မဳလဳယာန်။[၇][၈] ယဝ်ဒးပတုပ် နကဵုဥပမာမ္ဂး အခိင်ကာလ ကပ်ယဲအဳဗဝ်လာဝဳရုသ် (Ebola virus) မကတဵုဒှ် အကြာ ၂၀၁၃-၁၆ ဂှ် လၟောဝ်ဝက်သိန် သီုဖအိုတ် ဂစာန်ကၠောန် ၃၇ ဂှ် ဆဝက်သိန်မွဲဟေင် ကလိဂွံအခေါင်လာင်ဇြေန် သွက်ဂွံစကာ နဒဒှ် ဝက်သိန်၊ ညးမပ္တိတ်ဂှ် ခရိတ်စမ် ကာလစွမ်ဒုတိယ-တတိယဂှ် ဒးစကာသြန် ဒဝ်လာအမေရိကာန် ၜိုတ် ၁ ဗဳလဳယာန်။[၇]

ဂကောံ ရးနိဂီုနာနာ[ပလေဝ်ဒါန် | ပလေဝ်ဒါန် တမ်ကၞက်]

Access to COVID-19 Tools (ACT) Accelerator ကေုာံ COVAX[ပလေဝ်ဒါန် | ပလေဝ်ဒါန် တမ်ကၞက်]

ပရေင်ပံင်ကောံ ဂကောံဂၠးကဝ်နာနာ မပ္တံကဵု ဂကောံထတ်ယုက်ဂၠးကဝ် (WHO)၊ ဂကောံပံင်ကောံ သွက်ဂၠိုက်ဂၠာဲ အရာမဒစဵုဒစး ကပ်ယဲ(CEPI)၊ GAVI၊ Gates Foundation ကေုာံ သၟိင်ဍုင်ဂမၠိုင် ပံင်ကောံတုဲ ဒက်ပ္တန်လဝ် အေသဳတဳ (ACT) မဂွံအဓိပ္ပါယ် ကလိဂွံ ကပေါတ်သွက်ယဲကဝ်ဝိဒ်-၁၉ တအ် ပံင်ကောံတုဲ ဂၠာဲသြန်ဗွဝ် သွက်ဂွံထံက်ပင် ကမၠောန်လ္ၚတ်သုတေသန၊ ပ္တိတ်ကပေါတ်စွမ်ယဲ၊ ဂဥုဲလွဳ ကေုာံ ကဵုလာင်ဇြေန်ဝက်သိန် မဒှ်ပရေင်ကမၠောန် နကဵုက္ဍိုပ်လိက် "ကဝ်ဝဇ် ပိလ္လာရ် (COVAX Pillar)"။[၉][၁၀] နကဵု ကဝ်ဝက်ပိလ္လာရ်ဂှ် စွံလဝ် တင်ရန်တၟအ် ညံင်ဂွံကၠောန်ပ္တိတ် ဝက်သိန်ကဝ်ဝိဒ်-၁၉ ဗွဲမဂၠိုင်တုဲ လအိတ်သၞာံ ၂၀၂၁ မ္ဂး ညံင်ဂွံပ္တိတ် စဵုကဵု ၂ ဗဳလဳယာန်သွုင် သွက်ဂွံစဵုဒၞာ သၟာကမၠောန်ထတ်ယုက် ပ္ဍဲကိုပ်စၞေဟ် (frontline healthcare workers) ကေုာံ မၞိဟ်အန္တရာယ်ဇၞော် ကုကဝ်ဝိဒ်-၁၉ ပ္ဍဲဍုင်ဒိုက်ဂတ်တအ်ရ။[၁၁][၁၂]

ဂိတုဒဳဇြေမ်ဗါ ၂၀၂၀ ဂှ် နကဵုအေသဳတဳ ပ္ကောံဂွံသြန်ဒဝ်လာအမေရိကာန် ၂.၄ ဗဳလဳယာန်တုဲ နကဵု ကဝ်ဝက် ကေုာံ CEPI ဂွံဆဵုကေတ် လၟောဝ်ဝက်သိန် ဒစိတ် ရ။ ဂကောံဏအ်ဂှ် ဒှ်ဂကောံဇၞော်အိုတ် မဆေင်ကဵု ပ္ဍဲအရာမပ္တိတ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉တုဲ ပါလုပ်လဝ် သီုဖအိုတ် ဍုင် ၁၈၉ ရးနိဂီု။[၁၃][၁၄] သၞာံ ၂၀၂၀ လပါ်စဂှ် နကဵု ဂကောံထတ်ယုက်ဂၠးကဝ် ကလိဂွံ သြန်ထံက်ပင် နူကဵု ပန်စှ်ောဍုင် သြန်ဒဝ်လာအမေရိကာန် ၈ ဗဳလဳယာန် သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန်ရ။[၁၅]

ဂိတုဂျူလာင်ဂှ် ဂကောံထတ်ယုက်ဂၠးကဝ် လလောင်တြး ဍုင် ၁၆၅ ဍုင် မပစၞးကု ကောန်မၞိဟ်ဂၠးတိ ၆၀% တုပ်စိုတ် အစဳအဇန်ကဝ်ဝက်တုဲ ကဵုလဝ် ဂတိပါင် တုပ်လဝ်စိုတ် ကၞောတ်သၞာံ ၂၀၂၁ မ္ဂး ကောန်ဍုင်ညးတအ် ၂၀% ဂှ် သ္ကလိဂွံ ဝက်သိန်ရောင်။[၁၆]

ဂကောံပံင်ကောံဂၠးကဝ် သွက်စဵုဒၞာယဲကမၠောအ် (The Global Research Collaboration for Infectious Disease Preparedness - GLoPID-R) ဂှ် ပံင်တောဲကၠောန် ကုဂကောံထတ်ယုက်ဂၠးကဝ် ကေုာံ ရးနိဂီုဂမၠိုင် သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉။[၁၇][၁၈]တုဲပၠန် International Severe Acute Respiratory ကေုာံ Emerging Infection Consortium တအ်ဂှ် ဒှ်ဂကောံလ္ၚတ်မကဵုပရိုင်တင်ဂၞင် ပညာ ပ္ဍဲအရာမပသုတေသန ကဝ်ဝိဒ်-၁၉ ကေုာံ ကဵုပညာကုညးဍုင်ကွာန်တအ် သီုကဵု ပ္ဍဲအရာမပရးဝက်သိန်တအ်ရ။[၁၉]

ပ္ဍဲ ၄ ဂျောန်ဂှ် ပူဂိုလ် ကေုာံ သၟိင်ဍုင်ဂမၠိုင် ကၠောန်ဗဒှ် ကောံဓရီုသကိုပ်သက သုမ္မိတ် (summit) ပ္ဍဲဍုင်လာန်ဒါန်၊ ယူကေ၊ ဂှ် မၞိဟ်နူ ၅၂ ဍုင် တိုန်စိုပ်၊ သကိုပ်သကဍုင် ၃၅ ဍုင်၊ နူကဵု ဂျဳ၇ တအ်ကီု သီုကဵု ဂျဳ၂၀ဂှ် ကလိဂွံ သြန်ဗွဝ် ၈ ဗဳလဳယာန် သွက်ဂွံထံက်ပင် မဟာမိတ်ဂၠးကဝ် သွက်ဝက်သိန် ကေုာံ အိမ်မုန် (Global Alliance for Vaccines and Immunisation - GAVI) သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန် ကဝ်ဝိဒ်-၁၉တုဲ ကဵုဂဥုဲဝက်သိန် ကုကောန်ၚာ် ၃၀၀ ဗဳလဳယာန် မနွံပ္ဍဲဍုင်ဒိုက်ဂတ်တအ် ပ္ဍဲအကြာသၞာံ ၂၀၁၅ ရ။[၂၀]သြန်ဒါန် ဂၠိုင်အိုတ် ၁.၆ ဗဳလဳယာန် နူကဵု The Gates Foundation[၂၁] ကေုာံ သြန်ပံင်ဗြိတိန် ၃၃၀ မဳလဳယာန် ဇၟာပ်သၞာံ ပွိုင် မသုန်သၞာံ နူကဵု အလဵုအသဳဗြိတိန် (မတုပ်သၟဟ်ကဵု ဒဝ်လာအမေရိကာန် ၂.၁ ဗဳလဳယာန် ပ္ဍဲ ဂျောန် ၂၀၂၀)။[၂၀]

ပ္ဍဲဒဳဇြေမ်ဗါ ဂှ် နကဵု Gates Foundation ဆက်ကဵုဒါန် သြန်ဒဝ်လာ ၂၅၀ မဳလဳယာန်ပၠန် သွက်ဂွံကဵု ကပေါတ်စွမ်ကဝ်ဝိဒ်-၁၉၊ လွဳယဲ ကေုာံ ဝက်သိန် သွက်ဍုင်ဒိုက်ဂတ် ပ္ဍဲသၞာံ ၂၀၂၁ တုဲ သြန်ဗွဝ်သီုဖအိုတ် ဒှ်အာ သြန်ဒဝ်လာအမေရိကာန် ၁.၇၅ ဗဳလဳယာန်။[၂၂][၂၃]

ကမၠောန်[ပလေဝ်ဒါန် | ပလေဝ်ဒါန် တမ်ကၞက်]

လၟေင်အခိင် ဗွဲဓမ္မတာ မကၠောန်ပ္တိတ် ဝက်သိန်မွဲ နူစ စဵုကဵု ကမၠောန်တုဲဒှ်၊ မဒးကေတ်အခိင် အကြာ ၁၀ - ၁၅ သၞာံ

ဒဒှ်အတိက်[ပလေဝ်ဒါန် | ပလေဝ်ဒါန် တမ်ကၞက်]

ကိုပ်ကၠာ ကပ်ယဲကဝ်ဝိဒ်-၁၉ ဟွံကတဵုဒှ်ဏီဂှ် ဝက်သိန် သွက်စဵုဒၞာယဲဂှ် ဟွံဂွံကၠောန်ပ္တိတ် သၞာံဗွဲမလအ်ရ။ တုဲပၠန် ဝက်သိန် ဒစဵုဒစး ကဝ်ရဝ်နာဝဳရုသ် သွက်မၞိဟ်ဂှ်လေဝ် ဟွံကေင် နွံကၠုင်လဝ်ရ။[၂၄] ဆဂး ဝက်သိန် ဒစဵုဒစး ကဝ်ရဝ်နာဝဳရုသ် သွက်တိရစ္ဆာန်ဂှ် ကေင်ပ္တိတ်လဝ်နွံ မပ္တံကဵု သၞာံ ၂၀၀၃ သွက်ဂစေံ၊ ကၠဵု ကေုာံ ဗ္ဂဲ။[၂၅] တုဲပၠန် ဝိက်သိန် မဒစဵုဒစး ဝဳရုသ်ကဝ်ရဝ်နာ ဗဳဇမတုပ် မပကဵု ညံင်မၞိဟ်ဂွံဒှ်ယဲ သာ(SARS) ကေုာံ ယဲမာ(MERS)ကေင်နွံကၠုင်လဝ်ကီုရ။ ဝက်သိန် ဒစဵုဒစး ယဲသာ[၂၆] ကဵု ယဲမာ[၂၇]ဂှ်လေဝ် ဟွံကေင်စမ်လဝ် မၞိဟ် ဆစမ်လဝ် ကဵုတိရစ္ဆာန်သၟးရ။

အတိုင်လိက်မပ္တိတ်လဝ်မ္ဂး ပ္ဍဲသၞာံ ၂၀၀၅ ကဵု ၂၀၀၆ မ္ဂး သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန် ကေုာံ ဂဥုဲလွဳယဲသာဂှ် ဒှ်လဝ် အရာကိစ္စဇၞော် သၟိင်ဍုင်တအ်ကီုရ။[၂၈][၂၉][၃၀]ပ္ဍဲသၞာံ ၂၀၂၀ ဂှ် ဂဥုဲ ကေုာံ ဝက်သိန် သွက်ဂွံလွဳ ကေုာံ သွက်စဵုဒၞာ ယဲသာ ပ္ဍဲမၞိဟ် မကၠောန်ကမၠောန်ဇေတ်တ်ဂှ် ဟွံကလိဂွံဏီရ။[၃၁][၃၂]

တုဲပၠန် ဝက်သိန် စဵုဒၞာယဲမာလေဝ် ဟွံမဲဏီကီုရ။[၃၃] ကာလ ယဲမာကတဵုဒှ်ဂှ် တင်ဂၞင်သုတေသန မပလဝ် ပ္ဍဲအခိင်ယဲသာဂှ် ဒှ်အထံက်အရီုရောင် သွက််ဂွံကၠောန်ဗဒှ် ဝက်သိန်ရောင်ဂှ် စၟဳကေတ်လဝ်ကီုရ။[၃၁][၃၄] ၜိုတ်ဂိတုမာတ် ၂၀၂၀ ဂှ် ဝက်သိန်ယဲမာလဵုမွဲလေဝ် ဟွံစိုပ်ကဆံင် ကာလစွမ်ပထမ သွက်ဂွံစမ်မၞိဟ်ဏီ၊[၃၅] တုဲပၠန် ဂဥုဲတၞဟ်ပိဂှ် ဒှ်အခိင်အဃောမကၠောန်ဗဒှ် ဇၞော်ပၟဝ်ဒၟံင်၊ ဂဥုဲတအ်ဂှ် ChAdOx1-MERS, BVRS-GamVac ကေုာံ MVA-MERS-S တအ်ရ။[၃၆]

ကမၠောန် အလန်ကိုပ်ကၠာ[ပလေဝ်ဒါန် | ပလေဝ်ဒါန် တမ်ကၞက်]

ကြဴနူ မဂွံတီကေတ် ကဝ်ရဝ်နာဝဳရုသ် ကၞာတ်ကၠောအ်မၞိဟ် ပ္ဍဲ ဒဳဇြေမ်ဗါ ၂၀၁၉၊[၃၇]သဏ္ဌာန်ဗဳဇ ကဝ်ဝိဒ်-၁၉ ဂှ် ဗၟံက်ထ္ၜးမာန် ပ္ဍဲကဵု ၁၁ ဇာန်နဝါရဳ ၂၀၂၀တုဲ ဂကောံမၞိဟ်ဂၠးတိ လလောင်တြး သွက်ဂွံပလေဝ်စ ယဲကမၠောအ်ကမၞာန်တုဲ သ္ဒးကၠောန်ဗဒှ် ဝက်သိန် သွက်ဂွံ ဒစဵုဒစးယဲဏအ်ရောင်။[၆][၃၈][၃၉]

ၜိုတ် ဂိတုဖေဖဝ်ဝါရဳ ၂၀၂၀ နကဵု ဂကောံထတ်ယုက်ဂၠးကဝ်ဟီု၊ ဝက်သိန် ဒစဵုဒစး ယဲသာ၂ (SARS-CoV-2) (အခိင်ဂှ် ကော်စ ယဲသာ၂) အပ္ဍဲ ပွိုင် ၁၈ ဂိတုဏအ် ကလိဂွံဟွံမာန်။[၄၀] ပ္ဍဲသၞာံ ၂၀၂၀ လပါ်စဂှ် လၟိဟ်မၞိဟ်စမၠောအ် ယဲဝဝ်ဝိဒ်-၁၉ ဂှ် ဂၠိုင်ကၠုင်တုဲ ဂကောံသၟိင်ဍုင်ဂမၠိုင် ကေုာံ ဂကောံထတ်ယုက်ဂၠးကဝ်တအ် ချပ်ဂၞန်ရေင်သကအ် ညံင်သဂွံ ဝက်သိန် နကဵုဗွဲပရဟ်မာန်ဂှ် ဒးကၠောန်ရ။[၄၁]

ပ္ဍဲဂိတုဨပြဳ ၂၀၂၀ ဂှ် နကဵု ဂကောံထတ်ယုက်ဂၠးကဝ် တော်ကေတ် သွက်ဂွံကၠောန်ပ္တိတ် ဝက်သိန်ဂှ် ဒးစကာသြန် ဒဝ်လာအမေရိကာန် ၈ ဗဳလဳယာန်။[၄၁]

ၜိုတ်ဂိတု ဨပြဳ ၂၀၂၀ "ကမ္မဏဳ ကေုာံ အေန်သတဳကျုတ် ကြပ်ပေင် ၈၀ နူကဵု ၁၉ ရးနိဂီု" ဂှ် ကၠောန်ဒၟံင် သွက်ကလိဂွံ ဝက်သိန်ရ။[၄၂] ပ္ဍဲကဵု ဂိတုဨပြဳဂှ်ရ CEPI တော်ကေတ် လၟောဝ်ဝက်သိန်သီုဖအိုတ်ဂှ် ၜိုတ်တြဴဂှ် နကဵုဂကောံပံင်ကောံဂၠးကဝ် ရုဲစှ် သွက်ဂွံကၠောန် ကာလစွမ်ဒုတိယ-တတိယ၊ ဂွံဂွံ လာင်ဇြေန် ဂွံကလိဂွံဇမၞးမာန်ဂှ် အောန်အိုတ် ဒးစကာသြန် အမေရိကာန်ဒဝ်လာ ၂ ဗဳလဳယာန်။[၅][၄၃][၂၄] သမ္ၚေဝ်တၞဟ်တအ် ညာတ်ကေတ် လၟောဝ်ဝက်သိန် ၁၀ နွံပၟိက် သွက်ဂွံဇၞော်ပၟဝ် ကိုပ်ကၠာဟွံဂွံစိုပ် ကဆံင်လက္ကရဴအိုတ် သွက်ကလိဂွံလာင်ဇြေန်ရ။[၂၄]

ဝက်သိန်ဂမၠိုင်[ပလေဝ်ဒါန် | ပလေဝ်ဒါန် တမ်ကၞက်]

စိုပ် ၂၁ ဒဳဇြေမ်ဗါ ဂှ် ရးနိဂီုဂမၠိုင် ကေုာံ ကၟိန်ဍုင်ပံင်ကောံဥရောပ (အဳယူ)[၄၄] ကဵုအခေါင် ကေုာံ ပဒတန် ဝက်သေန် တဝ်ဇြိနမေရန် (tozinameran) ဗွဲမဂၠိုင် ကော်စ ဖရိဇြေရ်-ဗဳသြတေက် (Pfizer–BioNTech vaccine)။ ဍုင်ဗာရိုန် (Bahrain) ကဵု ဍုင်ပံင်ကောံအာရာပ် ဣမိရာတ် (United Arab Emirates) ပဒတန် ကဵုအခေါင်သွံ ဗွဲပရဟ် ကု BBIBP-CorV မကၠောန်ပ္တိတ် နူကဵု သိနဝ်ဖာမ် (Sinopharm) မဒှ်ဂကောံပ္တိတ်ဂဥုဲကြုက်ရ။[၄၅][၄၆]ဒဳဇြေမ်ဗါ ၁၆ ဂှ် နကဵု ကၟိန်ဍုင်ဨကရာဇ်ယူကေ မၞိဟ်ဂွံထ္ပက် ဝက်သိန် ၁၃၈,၀၀၀ တၠ မဒှ်သတ္တဟကိုပ်ကၠာအိုတ် မစထ္ပက်ဝက်သိန်ဂှ်ရ။[၄၇] ဒဳဇြေမ်ဗါ ၁၁၊ ၂၀၂၀ ဂှ် နကဵု ရးနိဂီုပံင်ကောံအမေရိကာန် ကဵုအခေါင် ပဒတန် ဗွဲပရဟ် ကုတဝ်ဇြိနမေရန်။[၄၈] သတ္တာဟဂတဂှ် ညးတအ် ပဒတန် ကု mRNA-1273 မကၠောန်ပ္တိတ် နူကဵု မဝ်ဒေရ်နာဝိသိန် (Moderna vaccine)ရ။[၄၉][၅၀][၅၁]

ဝက်သိန်မွဲမွဲ ကၠောန်လဝ်တုဲ ဒးစမ်ၜတ် ပိကဆံင်၊ ညးကော်စ ကာလစွမ်ပထမ၊ ကာလစွမ်ဒုတိယ၊ ကေုာံ ကာလစွမ်တတိယ။ ကာလစွမ်ပထမဂှ် စမ်ရံင် ဂဥုဲဂှ် ကဵုအန္တရာယ် ကုမၞိဟ်မာန်ဟွံမာန် ကေုာံ မွဲသွုင်မ္ဂး ဂလိုင်လဵုဂွံစုတ်ရ။ ပ္ဍဲကာလဂှ်မ္ဂး ညးစမ် မၞိဟ်ပရေင်ထတ်ယုက်ထတ်တ် လၟိဟ်ၜိုတ် ၜါပိဒါဇြေန် (ၜိုတ် ပိစှ်ော)။ ကာလစွမ်ဒုတိယဂှ် အတိုင်သွဟ်မကလိဂွံ နူကဵုကာလစွမ်ပထမဂှ် ပညဳပညပ် ပလေဝ်တုဲ ဆက်စမ် မၞိဟ်မဂၠိုင်ကဵုကၠံ (သၟဝ်လ္ၚီ)။[၅၂][၅၃]ကာလစွမ် ပထမ-ဒုတိယ ဂှ် စမ်မဆေင်ကဵု ပရေင်ဂီုကၠီု ကေုာံ ဒြဟတ်အိမ်မုန် ဗွဲမဂၠိုင် မစမ် အစောမ်သတ္တိဂဥုဲ ကေုာံ အရာမကတဵုဒှ်မာန် မသ္ၚေဝ်ဂၠေပ် ဗွဲမချိုတ်ပၠိုတ်ရ။[၅၃]ကာလစွမ်တတိယဂှ်မ္ဂး ဒးစမ်ၜတ် မၞိဟ်ဂၠိုင်ဂၠိုင် နကဵုမၞိဟ်နာနာသာ်၊ မၞိဟ်အာယုက်ဇၞော်၊ မၞိဟ်အာယုက်ဍောတ်၊ မၞိဟ်ပရေင်ထတ်ယုက် ဍိုန်လျ၊ မၞိဟ်ပရေင်ထတ်ယုက်ခိုဟ်၊ တုဲပၠန် မၞိဟ်သွက်ဂွံၜတ်ကၞာတ် မကော်ဂး control group၊ ဝက်သိန်ၜိုတ်လဵု ကၠောန်ကမၠောန် ပ္ဍဲအရာဒစဵုဒစး ယဲဂှ်ရ။[၅၂][၅၃] သွဟ်ပွံက်ဝက်သိန် ဂလိုင်လဵုဂီုကၠီု၊ ဂလိုင်လဵုမကၠောန်ကမၠောန် ကေုာံ စကာ နဒဒှ် ဂဥုဲဂွံ ဟွံဂွံတအ်ဂှ် ဒုင်သဇိုင် ကုသွဟ် နူကဵုကာလစွမ်တတိယဏအ်ရ။[၅၄][၅၅][၅၆]

ဝက်သိန်ဂမၠိုင် မဂွံလဝ် အခေါင် ကေုာံ ဒတန်[ပလေဝ်ဒါန် | ပလေဝ်ဒါန် တမ်ကၞက်]

ဝက်သိန်ဂမၠိုင် မဂွံလဝ် အခေါင် သွက်ကာပရဟ် ဟွံသေင်မ္ဂး ဒတန် သွက်ဂွံစကာ
Vaccines authorized for emergency use or approved for full use
ဗီုရုပ် လၟောဝ်ဝက်သိန်ဂမၠိုင်
ညးမကၠောန် ကေုာံ ညးမဒုင်ပစ္စဲ
Vaccine candidates,
developers, and sponsors 		ကွတ်
Technology 		ကာလစွမ် လၟုဟ်
Current phase (participants)
design 		ကာလစွမ် မစိုပ်ဒတုဲ (ညးမပါလုပ်ဂမၠိုင်)
မကၠောန်ကမၠောန် ပ္ဍဲအိမ်မုန်
Completed phase[lower-alpha ၁] (participants)
Immune response 		မကဵုအခေါင်စကာ နဒဒှ် ကာတၟေင်
Emergency use authorization 		ဍုင်မကဵုအခေါင် ပလဝ်ဒတန်
Full authorization
Covid19 vaccine biontech pfizer 3.jpg Tozinameran[၅၇][၅၈][၅၉]
BioNTech, Pfizer, Fosun Pharma

Trade name: Comirnaty

modRNA Phase III (၄၃,၄၄၈)[၆၀]

Positive results from an interim analysis were announced on 18 November 2020[၆၁] and published on 10 December 2020 reporting an overall efficacy of 95%.[၆၂][၆၃][၆၄]
Randomized, placebo-controlled
Location(s): Germany, United States
Duration: Jul 2020 – Nov 2020[၆၅][၆၆]

Phase I–II (၄၅)
Strong RBD-binding IgG and neutralizing antibody response peaked 7 days after a booster dose, robust CD4+ and CD8+ T cell responses, undetermined durability[၆၇][၆၈]
Duration: May. 2020 – 		Authorized
 Authorized
Moderna COVID-19 vaccine (2020).jpg mRNA-1273[၁၀၃][၁၀၄]
Moderna, NIAID, BARDA, CEPI 		Lipid nanoparticle dispersion containing modRNA Phase III (၃၀၀၀၀)
Interventional; randomized, placebo-controlled study for efficacy, safety, and immunogenicity.

Positive results from an interim analysis were announced on 15 November 2020[၁၀၅] and published on 30 December 2020 reporting an overall efficacy of 94.1%.[၁၀၆]
Location(s): United States
Duration: Jul 2020 – Oct 2022

Phase I–II (၇၂၀)[၁၀၇][၁၀၈]
Dose-dependent neutralizing antibody response on two-dose schedule; undetermined durability.[၁၀၉][၁၁၀][၁၁၁]
Location(s): United States
Duration: Mar 2020 – Nov 2021 		Authorized
 Authorized
Вакцина Спутник V.jpg Gam-COVID-Vac
Gamaleya Research Institute of Epidemiology and Microbiology;
Trade name: Sputnik V 		Non-replicating viral vector (adenovirus) Phase III (၄၀,၀၀၀)
Randomized double-blind, placebo-controlled to evaluate efficacy, immunogenicity, and safety[၁၂၃]
Location(s): Russia, Belarus,[၁၂၄] India,[၁၂၅][၁၂၆] Venezuela,[၁၂၇] UAE [၁၂၈]
Duration: Aug 2020 – May 2021 		Phase I–II (၇၆)
Neutralizing antibody and T cell responses.[၁၂၉]
Location(s): Russia
Duration: Jun 2020[၁၂၉] - Sep 2020 		Authorized
SINOVAC COVID-19 vaccine.jpg CoronaVac[၁၃၉][၁၄၀][၁၄၁]
Sinovac 		Inactivated SARS-CoV-2 Phase III (၃၃,၆၂၀)
Double-blind, randomized, placebo-controlled to evaluate efficacy and safety.

Positive results from an interim analysis of a small sample were announced by Turkey on 24 December 2020, with an efficacy of 91%.[၁၄၂] Additional results were announced by Brazil on 7 January 2021, with a subgroup efficacy of 78%[၁၄၃] for symptomatic cases requiring medical assistance (severity grade 3 on the WHO Clinical Progression Scale);[၁၄၄] and by Indonesia on 11 January, with an overall efficacy of 65.3%.[၁၄၅] The vaccine was 50.4 per cent effective at preventing symptomatic infections in a Brazilian trial.[၁၄၆]
Location(s): Brazil (15,000);[၁၄၇] Chile (3,000);[၁၄၈] Indonesia (1,620); Turkey (13,000)[၁၄၉]
Duration: Jul 2020 – Oct 2021 in Brazil; Aug 2020 – Jan 2021 in Indonesia

Phase II (၆၀၀)
Immunogenicity eliciting 92% seroconversion at lower dose and 98% at higher dose after 14 days[၁၅၀]
Location(s): China
Duration: May 2020 - 		Authorized
AstraZeneca COVID-19 Vaccine.jpg AZD1222[lower-alpha ၂][lower-alpha ၃][၁၅၈][၁၅၉][၁၆၀]
University of Oxford, AstraZeneca, CEPI 		Modified chimpanzee adenovirus vector (ChAdOx1) Phase III (၃၀၀၀၀)
Interventional; randomized, placebo-controlled study for efficacy, safety, and immunogenicity.[၁၆၁]

Positive results from an interim analysis of four ongoing trials were announced on 23 November 2020 and published on 8 December 2020.[၁၆၂] Overall efficacy was 70%, ranging from 62% to 90% with different dosing regimens, with a peer-reviewed safety profile.[၁၆၂]
Location(s): Brazil (5,000),[၁၆၃] United Kingdom, India[၁၆၄]
Duration: May 2020 – Aug 2021

Phase I–II (၅၄၃)
Spike-specific antibodies at day 28; neutralizing antibodies after a booster dose at day 56[၁၆၅] 		Authorized
_ BBIBP-CorV[၁၇၆]
Sinopharm: Beijing Institute of Biological Products, Wuhan Institute of Biological Products 		Inactivated SARS-CoV-2 (vero cells) Phase III (၄၈၀၀၀)
Randomized, double-blind, parallel placebo-controlled, to evaluate safety and protective efficacy.

Positive results from an interim analysis were announced by the United Arab Emirates on 9 December 2020.[၁၇၇] Sinopharm's internal analysis indicated a 79% efficacy.[၁၇၈]
Location(s): United Arab Emirates, Bahrain, Jordan,[၁၇၉] Argentina,[၁၈၀] Morocco,[၁၈၁] Peru[၁၈၂]
Duration: Jul 2020 – Jul 2021

Phase I–II (၃၂၀)
Neutralizing antibodies at day 14 after 2 injections[၁၈၃]
Location(s): China
Duration: Apr 2020 – Jun 2020 		Authorized Authorized

_ BBV152

Bharat Biotech, Indian Council of Medical Research
Trade name: Covaxin

Inactivated SARS-CoV-2 Phase III (၂၅၈၀၀)
Randomised, observer-blinded, placebo-controlled[၁၈၈]
Location(s): India[၁၈၉]
Duration: Nov 2020 – Mar 2021 		Phase I (၃၇၅) Dose-dependent neutralizing antibody response on two-dose schedule.

Pending Phase II reports[၁၉၀]

Authorized
_ EpiVacCorona [ထာမ်ပလိက်:Separated entries][၁၉၁]
Vector 		Vaccine based on peptide antigens[၁၉၁]) Phase III (၄၀,၀၀၀)
Randomized double-blind, placebo-controlled to evaluate efficacy, immunogenicity, and safety
Location(s): Russia [၁၉၂]
Duration: Nov 2020 – ? 		Phase I–II (၁၀၀)
Simple, blind, placebo-controlled, randomized study of safety, reactogenicity and immunogenicity[၁၉၁]
Location(s): Russia
Duration: Jul 2020[၁၉၁] - Sep 2020[၁၉၃] 		Authorized
_ Ad5-nCoV
CanSino Biologics, Beijing Institute of Biotechnology of the Academy of Military Medical Sciences

Trade name: Convidicea

Recombinant adenovirus type 5 vector Phase III (၄၀,၀၀၀)
global multi-center, randomized, double-blind, placebo-controlled to evaluate efficacy, safety and immunogenicity.
Location(s): China, Argentina, Chile,[၁၉၆] Mexico,[၁၉၇] Pakistan,[၁၉၈] Russia,[၁၉၉] Saudi Arabia[၂၀၀][၂၀၁]
Duration: Mar. – Dec. 2020, China; Sep. 2020 – Dec. 2021, Pakistan; Sep. 2020 – Nov. 2020, Russia[၁၉၉] 		Phase II (၅၀၈)
Neutralizing antibody and T cell responses[၂၀၂] 		Authorized

လၟောဝ်ဝက်သိန်ဂမၠိုင် Vaccine candidates[ပလေဝ်ဒါန် | ပလေဝ်ဒါန် တမ်ကၞက်]

လၟောဝ်ဝက်သိန် ကဝ်ဝိဒ်=၁၉ မနွံပ္ဍဲကာလစွမ် ပထမ-တတိယ
COVID‑19 candidate vaccines in Phase I–III trials[၂၀၅][၂၀၆][၂၀၇]
လၟောဝ်ဝက်သေန်ဂမၠိုင်
ညးမကၠောန်ဗဒှ် ကေုာံ ညးမဒုင်ပစ္စဲ
Vaccine candidates,
developers, and sponsors 		ကွတ်
Technology 		ကာလစွမ် လၟုဟ်
Current phase (participants)
design 		ကာလစွမ်မတုဲဒှ်
Completed phase[lower-alpha ၄] (participants)
Immune response 		မကဵုအခေါင်စကာ နဒဒှ် ကာတၟေင်
Emergency use authorization
Ad26.COV2.S[၂၀၈][၂၀၉]

Janssen Pharmaceutica (Johnson & Johnson), BIDMC

Non-replicating viral vector (adenovirus serotype 26) Phase III (၄၀၀၀၀)
Randomized, double-blinded, placebo-controlled

Temporarily paused on 13 October 2020, due to an unexplained illness in a participant.[၂၁၀] Johnson & Johnson announced, on 23 October, that they are preparing to resume the trial in the US.[၂၁၁][၂၁၂]
Location(s): United States, Argentina, Brazil, Chile, Colombia, Mexico, Peru, the Philippines, South Africa and Ukraine
Duration: Jul 2020 – 2023

Phase I–II (၁၀၄၅) Pending
NVX-CoV2373[၂၁၅]
Novavax 		SARS-CoV-2 recombinant spike protein nanoparticle with adjuvant Phase III (၄၅၀၀၀)
Randomised, observer-blinded, placebo-controlled trial[၂၁၆]
Location(s): UK, India (15000);[၂၁၇] US, Mexico (30000)[၂၁၈]
Duration: Sep 2020 – Jan 2021 (UK, India); Dec 2020 – Mar 2021 (US, Mexico) 		Phase I–II (၁၃၁) IgG and neutralizing antibody response with adjuvant after booster dose[၂၁၉] Pending
BBV152

Bharat Biotech, Indian Council of Medical Research

Trade name:Covaxin

Inactivated SARS-CoV-2 Phase III (၂၅၈၀၀)
Randomised, observer-blinded, placebo-controlled[၂၂၁]
Location(s): India
Duration: Nov 2020 – Mar 2022 		Phase I (၃၇၅) Dose-dependent neutralizing antibody response on two-dose schedule.

Pending Phase II reports[၂၂၂]

Pending
CoVLP[၂၂၄]

Medicago, GSK

Recombinant, plant-based virus-like particles[lower-alpha ၅] with GSK adjuvant Phase II–III (၃၀,၆၁၂)
Event-driven, randomized, observer blinded, placebo-controlled[၂၂၆]
Location(s): Canada
Duration: Nov 2020 – Apr 2022 		Phase I (၁၈၀)
Neutralizing antibodies at day 42 after the first injection (day 21 after the second injection) were at levels 10x that of COVID-19 survivors.
ZF2001 [၂၀၅]
Anhui Zhifei Longcom Biopharmaceutical Co. Ltd.

Trade name: RBD-Dimer

Recombinant subunit vaccine Phase III (၂၉,၀၀၀)
randomized, double-blind, placebo-controlled[၂၂၇]
Location(s): China, Ecuador, Indonesia, Malaysia, Pakistan, Uzbekistan[၂၂၈][၂၂၉]
Duration: Dec 2020 – Apr 2022 		Phase II (၉၀၀)
Interventional; randomized, double-blind, placebo-controlled[၂၃၀]
Location(s): Chongqing
Duration: Jun 2020 – Sep 2021
Zorecimeran (CVnCoV)
CureVac, CEPI 		modRNA Phase III (၃၆၅၀၀)[၂၃၁]
Phase 2b/3: Multicenter efficacy and safety trial in adults
Location(s): Argentina, Belgium, Colombia, Dominican Republic, France, Germany, Mexico, Netherlands, Panama, Peru, Spain
Duration: Nov 2020 – ? 		Phase I–II (၉၄၄)[၂၃၂][၂၃၃]
Phase 1 (284): Partially blind, controlled, dose-escalation to evaluate safety, reactogenicity and immunogenicity.

Phase 2a (660):Partially observer-blind, multicenter, controlled, dose-confirmation.
Location(s): Belgium (P1), Germany (P1), Panama (2a), Peru (2a)
Duration: Jun 2020 – Oct 2021

IIBR-100[၂၃၄]
The Israel Institute for Biological research

Trade name: Brilife

Recombinant vesicular stomatitis virus Phase II (၁၀၀၀)[၂၃၅]
Location(s): Israel
Duration: Dec 2020 – spring 2021 		Phase I (၈၀)[၂၃၄]
Subjects (18-55 years old) randomly receiving a single administration of IIBR-100 at the low, mid, or high dose of saline or two administrations at a low dose, or saline, 28 days apart.
Location(s): Israel
Duration: Oct – Nov 2020
INO-4800[lower-alpha ၆][၂၃၆][၂၃၇]
Inovio, CEPI, Korea National Institute of Health, International Vaccine Institute 		DNA plasmid delivered by electroporation Phase I–II (၄၀)
Location(s): United States, South Korea
Duration: Apr–Nov 2020 		Pending Phase I report
EpiVacCorona[၁၉၁]
Vector 		Vaccine based on peptide antigens[၁၉၁] Phase I–II (၁၀၀)
Simple, blind, placebo-controlled, randomized study of safety, reactogenicity and immunogenicity[၁၉၁]
Location(s): Russia
Duration: Jul 2020[၁၉၁] – ? 		Pending Phase I–II report
Unnamed[၂၃၈]
Chinese Academy of Medical Sciences 		Inactivated SARS-CoV-2 Phase I–II (၉၄၂)
Randomized, double-blinded, single-center, placebo-controlled
Location(s): Chengdu
Duration: Jun 2020 – Sep 2021
AG0301-COVID‑19[၂၃၉]
AnGes Inc.,[၂၄၀] AMED 		DNA plasmid Phase I–II (၃၀)
Non-randomized, single-center, two doses
Location(s): Osaka
Duration: Jun 2020 – Jul 2021
Lunar-COV19/ARCT-021[၂၄၁][၂၄၂]

Arcturus Therapeutics

mRNA Phase I–II (၉၂)
Randomized, double-blinded
Location(s): Singapore
Duration: Aug 2020 – ?
COVID‑19/aAPC[၂၄၃]
Shenzhen Genoimmune Medical Institute[၂၄၄] 		Lentiviral vector with minigene modifying aAPCs Phase I (၁၀၀)
Location(s): Shenzhen
Duration: Mar 2020 – 2023
LV-SMENP-DC[၂၄၅]
Shenzhen Genoimmune Medical Institute[၂၄၄] 		Lentiviral vector with minigene modifying DCs Phase I (၁၀၀)
Location(s): Shenzhen
Duration: Mar 2020 – 2023
LNP-nCoVsaRNA[၂၄၆]
MRC clinical trials unit at Imperial College London 		mRNA Phase I (၁၀၅)
Randomized trial, with dose escalation study (15) and expanded safety study (at least 200)
Location(s): United Kingdom
Duration: Jun 2020 – Jul 2021
ZyCoV-D[၂၄၇]

Cadila Healthcare

DNA plasmid expressing SARS-CoV-2 S protein Phase I–II (၁၀၀၀)
Interventional; randomized, double-blind, placebo-controlled[၂၄၈][၂၄၉]
Location(s): India
Duration: Jul 2020 – Apr 2021
GX-19[၂၅၀][၂၅၁]
Genexine consortium,[၂၅၂] International Vaccine Institute 		DNA Phase I (၄၀)
Location(s): Seoul
Duration: Jun 2020 – Jun 2022
SCB-2019[၂၅၃][၂၅၄]
Clover Biopharmaceuticals,[၂၅၅] GSK 		Spike protein trimeric subunit with GSK adjuvant Phase I (၁၅၀)
Location(s): Perth
Duration: Jun 2020 – Mar 2021
COVAX-19[၂၅၆]
Vaxine Pty Ltd[၂၅၇] 		Recombinant protein Phase I (၄၀)
Location(s): Adelaide
Duration: Jun 2020 – Jul 2021
Unnamed[၂၅၈]
PLA Academy of Military Science, Walvax Biotech[၂၅၉] 		mRNA Phase I (၁၆၈)
Location(s): China
Duration: Jun 2020 – Dec 2021
SARS-CoV-2 Sclamp/V451[၂၆၀][၂၆၁]
UQ, Syneos Health, CEPI, Seqirus 		Molecular clamp stabilized spike protein with MF59 Phase I (၁၂၀)
Randomised, double-blind, placebo-controlled, dose-ranging
Location(s): Brisbane
Duration: Jul–Oct 2020 		ထာမ်ပလိက်:NA
Testing and development terminated in December 2020 due to false positive HIV test found among participants

နိဿဲ[ပလေဝ်ဒါန် | ပလေဝ်ဒါန် တမ်ကၞက်]

  1. ↑ Santiago, Jahleah (2020-12-19). A side-by-side comparison of the Pfizer/BioNTech and Moderna vaccines (in en-US).
  2. ↑ "How COVID vaccines are being divvied up around the world Canada leads the pack in terms of doses secured per capita" (30 November 2020). Nature. doi:10.1038/d41586-020-03370-6. PMID 33257891. 
  3. ↑ So, Anthony D (December 2020). "Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis". BMJ. doi:10.1136/bmj.m4750. ISSN 1756-1833. 
  4. ↑ Beaumont၊ Peter။ "Covid-19 vaccine: who are countries prioritising for first doses?" (in en-GB)၊ The Guardian၊ 2020-11-18။ 
  5. ↑ ၅.၀ ၅.၁ ၅.၂ "Evolution of the COVID-19 vaccine development landscape" (4 September 2020). Nature Reviews Drug Discovery 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. ISSN 1474-1776. PMID 32887942. 
  6. ↑ ၆.၀ ၆.၁ နိဿဲ ဗၠေတ် - Invalid <ref> tag; no text was provided for refs named thanh
  7. ↑ ၇.၀ ၇.၁ "Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study" (December 2018). Lancet Global Health 6 (12): e1386–96. doi:10.1016/S2214-109X(18)30346-2. PMID 30342925. 
  8. ↑ "Innovation in the pharmaceutical industry: New estimates of R&D costs" (May 2016). Journal of Health Economics 47: 20–33. doi:10.1016/j.jhealeco.2016.01.012. PMID 26928437. 
  9. ↑ What is the ACT Accelerator?. World Health Organization (2020).
  10. ↑ What is COVAX?. GAVI (2020-09-01).
  11. ↑ COVAX: CEPI's response to COVID-19. Coalition for Epidemic Preparedness Innovations (CEPI) (2020).
  12. ↑ New vaccines for a safer world. CEPI (2020).
  13. ↑ Our portfolio: partnerships to develop vaccines against COVID-19. CEPI (2020).
  14. ↑ Global equitable access to COVID-19 vaccines estimated to generate economic benefits of at least US$ 153 billion in 2020–21, and US$ 466 billion by 2025, in 10 major economies, according to new report by the Eurasia Group. World Health Organization (4 December 2020).
  15. ↑ Wake, Damon (2020-05-04). EU spearheads $8 billion virus fundraiser. Yahoo Finance.
  16. ↑ Script error: The module returned a nil value. It is supposed to return an export table.
  17. ↑ GloPID: Novel coronavirus COVID-19. “GloPID-R Members and other major players involved in infectious disease outbreaks worldwide reacted rapidly to this emerging epidemic, working closely with the WHO to identify the specific funding research priorities needed to tackle the disease.”
  18. ↑ နိဿဲ ဗၠေတ် - Invalid <ref> tag; no text was provided for refs named can-research
  19. ↑ ISARIC: COVID-19 clinical research resources. ISARIC (2020-04-27).
  20. ↑ ၂၀.၀ ၂၀.၁ Global Vaccine Summit 2020: World leaders make historic commitments to provide equal access to vaccines for all. Global Alliance for Vaccines and Immunisation (2020-06-04).
  21. ↑ Script error: The module returned a nil value. It is supposed to return an export table.
  22. ↑ "Bill and Melinda Gates Foundation announces $250 million COVID vaccine commitment"၊ ABC News - Technology၊ 10 December 2020။ 
  23. ↑ "Bill and Melinda Gates call for collaboration, continued innovation to overcome challenges of delivering COVID-19 scientific breakthroughs to the world"၊ Bill & Melinda Gates Foundation၊ 9 December 2020။ 
  24. ↑ ၂၄.၀ ၂၄.၁ ၂၄.၂ နိဿဲ ဗၠေတ် - Invalid <ref> tag; no text was provided for refs named gates2
  25. ↑ "Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus" (December 2003). Avian Pathology 32 (6): 567–82. doi:10.1080/03079450310001621198. PMID 14676007. 
  26. ↑ "Effects of a SARS-associated coronavirus vaccine in monkeys" (December 2003). Lancet 362 (9399): 1895–96. doi:10.1016/S0140-6736(03)14962-8. PMID 14667748. 
  27. ↑ "Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice" (October 2014). Vaccine 32 (45): 5975–82. doi:10.1016/j.vaccine.2014.08.058. PMID 25192975. 
  28. ↑ "Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice" (February 2005). The Journal of Infectious Diseases 191 (4): 507–14. doi:10.1086/427242. PMID 15655773. 
  29. ↑ "Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins" (September 2005). Journal of Virological Methods 128 (1–2): 21–28. doi:10.1016/j.jviromet.2005.03.021. PMID 15885812. 
  30. ↑ "Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters" (March 2006). The Journal of Infectious Diseases 193 (5): 685–92. doi:10.1086/500143. PMID 16453264. 
  31. ↑ ၃၁.၀ ၃၁.၁ "Development of SARS vaccines and therapeutics is still needed" (January 2013). Future Virology 8 (1): 1–2. doi:10.2217/fvl.12.126. PMID 32201503. 
  32. ↑ SARS (severe acute respiratory syndrome). National Health Service (5 March 2020).
  33. ↑ "Middle East respiratory syndrome coronavirus: a comprehensive review" (January 2016). Frontiers of Medicine 10 (2): 120–36. doi:10.1007/s11684-016-0430-6. PMID 26791756. 
  34. ↑ "SARS veterans tackle coronavirus" (October 2012). Nature 490 (7418). doi:10.1038/490020a. PMID 23038444. Bibcode: 2012Natur.490...20B. 
  35. ↑ "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial" (September 2019). The Lancet. Infectious Diseases 19 (9): 1013–22. doi:10.1016/S1473-3099(19)30266-X. PMID 31351922. 
  36. ↑ "Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus" (2019). Frontiers in Microbiology 10. doi:10.3389/fmicb.2019.01781. PMID 31428074. 
  37. ↑ World Health Organization timeline – COVID-19. World Health Organization (27 April 2020).
  38. ↑ နိဿဲ ဗၠေတ် - Invalid <ref> tag; no text was provided for refs named gates1
  39. ↑ "Covid-19: Navigating the uncharted" (March 2020). The New England Journal of Medicine 382 (13): 1268–69. doi:10.1056/nejme2002387. PMID 32109011. 
  40. ↑ Here's why the WHO says a coronavirus vaccine is 18 months away (14 February 2020).
  41. ↑ ၄၁.၀ ၄၁.၁ Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine. World Health Organization (27 April 2020). “It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.”
  42. ↑ "Genetic Engineering Could Make a COVID-19 Vaccine in Months Rather Than Years"၊ Scientific American၊ 1 June 2020။ 
  43. ↑ နိဿဲ ဗၠေတ် - Invalid <ref> tag; no text was provided for refs named yamey
  44. ↑ ၄၄.၀ ၄၄.၁ Questions and Answers: COVID-19 vaccination in the EU (21 December 2020).
  45. ↑ "Bahrain second in the world to approve the Pfizer/BioNTech Covid-19 vaccine"၊ Bahrain News Agency၊ 4 December 2020။ 
  46. ↑ "UAE: Ministry of Health announces 86 per cent vaccine efficacy"၊ Gulf News။ 
  47. ↑ Campbell၊ Denis။ "138,000 people in UK receive Covid vaccine in first week"၊ 16 December 2020။ 
  48. ↑ "F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away"၊ The New York Times၊ 12 December 2020။ 
  49. ↑ ၄၉.၀ ၄၉.၁ Script error: The module returned a nil value. It is supposed to return an export table.
  50. ↑ ၅၀.၀ ၅၀.၁ "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020" (December 2020). MMWR. Morbidity and Mortality Weekly Report 69 (5152): 1653–1656. doi:10.15585/mmwr.mm695152e1. 
  51. ↑ "FDA approves second Covid vaccine for emergency use as it clears Moderna's for U.S. distribution"၊ CNBC၊ 19 December 2020။ 
  52. ↑ ၅၂.၀ ၅၂.၁ Vaccine Safety – Vaccines. US Department of Health and Human Services.
  53. ↑ ၅၃.၀ ၅၃.၁ ၅၃.၂ The drug development process. U.S. Food and Drug Administration (FDA) (4 January 2018).
  54. ↑ နိဿဲ ဗၠေတ် - Invalid <ref> tag; no text was provided for refs named cohen6-19
  55. ↑ How flu vaccine effectiveness and efficacy are measured. Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, US Department of Health and Human Services (29 January 2016).
  56. ↑ Principles of epidemiology, Section 8: Concepts of disease occurrence. Centers for Disease Control and Prevention, Center for Surveillance, Epidemiology, and Laboratory Services, US Department of Health and Human Services (18 May 2012).
  57. ↑ ၅၇.၀ ၅၇.၁ Regulatory Decision Summary – Pfizer-BioNTech COVID-19 Vaccine. Health Canada, Government of Canada (9 December 2020).
  58. ↑ Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults. United States National Library of Medicine (30 April 2020).
  59. ↑ A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults. European Union (14 April 2020).
  60. ↑ Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine. Pfizer.
  61. ↑ Pfizer says final data analysis shows Covid vaccine is 95% effective, plans to submit to FDA in days. CNBC (18 November 2020).
  62. ↑ "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine" (December 2020). New England Journal of Medicine 383 (27): 2603–2615. doi:10.1056/NEJMoa2034577. PMID 33301246. 
  63. ↑ Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine. Pfizer.
  64. ↑ ထာမ်ပလိက်:Cite report ထာမ်ပလိက်:PD-notice
  65. ↑ Erman၊ Michael။ "Pfizer ends COVID-19 trial with 95% efficacy, to seek emergency-use authorization"၊ Reuters၊ 18 November 2020။ 
  66. ↑ နိဿဲ ဗၠေတ် - Invalid <ref> tag; no text was provided for refs named NYT-20201120
  67. ↑ Tiggle၊ Nick။ "Covid-19 vaccine: Allergy warning over new jab"၊ BBC News၊ 9 December 2020။ 
  68. ↑ "Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults" (October 2020). Nature 586 (7830): 589–593. doi:10.1038/s41586-020-2639-4. PMID 32785213. 
  69. ↑ UK medicines regulator gives approval for first UK COVID-19 vaccine. Medicines and Healthcare Products Regulatory Agency, Government of the UK (2 December 2020).
  70. ↑ Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine (8 December 2020).
  71. ↑ Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine (3 December 2020).
  72. ↑ Bahrain becomes second country to approve Pfizer COVID-19 vaccine. Al Jazeera.
  73. ↑ ၇၃.၀ ၇၃.၁ ၇၃.၂ Drug and vaccine authorizations for COVID-19: List of applications received. Health Canada, Government of Canada (9 December 2020).
  74. ↑ Script error: The module returned a nil value. It is supposed to return an export table. ထာမ်ပလိက်:PD-notice
  75. ↑ Pfizer-BioNTech COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers (PDF). Pfizer (11 December 2020).
  76. ↑ "Mexico Approves Pfizer Vaccine for Emergency Use as Covid Surges"၊ Bloomberg၊ 12 December 2020။ 
  77. ↑ Kuwait authorizes emergency use of Pfizer-BioNTech COVID-19 vaccine (13 December 2020).
  78. ↑ Singapore approves use of Pfizer's COVID-19 vaccine (14 December 2020).
  79. ↑ Jordan approves Pfizer-BioNTech Covid vaccine. France 24 (15 December 2020).
  80. ↑ "Oman issues licence to import Pfizer BioNTech Covid vaccine – TV"၊ Reuters၊ 15 December 2020။ 
  81. ↑ Costa Rica authorizes Pfizer-BioNTech coronavirus vaccine (16 December 2020).
  82. ↑ Arcsa autoriza ingreso al país de vacuna Pfizer-BioNTech para el Covid-19 – Agencia Nacional de Regulación, Control y Vigilancia Sanitaria (in es).
  83. ↑ Israeli Health Minister 'pleased' as FDA approves Pfizer COVID-19 vaccine.
  84. ↑ Panama approves Pfizer's COVID-19 vaccine – health ministry. Yahoo! Finance.
  85. ↑ Chile approves Pfizer-BioNTech Covid-19 vaccine for emergency use (17 December 2020).
  86. ↑ Qatar, Oman to receive Pfizer-BioNTech COVID-19 vaccine this week. Reuters.
  87. ↑ Dubai approves the Pfizer-BioNTech vaccine which will be free of charge (23 December 2020).
  88. ↑ Coronavirus en la Argentina: La ANMAT aprobo el uso de emergencia de la vacuna Pfizer (in es).
  89. ↑ Iraq grants emergency approval for Pfizer COVID-19 vaccine. MSN.
  90. ↑ Script error: The module returned a nil value. It is supposed to return an export table.
  91. ↑ "Colombia regulator approves Pfizer-BioNTech vaccine for emergency use"၊ Reuters၊ 6 January 2021။ 6 January 2021 တင်နိဿဲဏအ် စၟဳစၟတ်တုဲ။ 
  92. ↑ Coronavirus: Saudi Arabia approves Pfizer COVID-19 vaccine for use (10 December 2020).
  93. ↑ "Coronavirus Vaccine Tracker"၊ The New York Times၊ 10 June 2020။ 
  94. ↑ Script error: The module returned a nil value. It is supposed to return an export table.
  95. ↑ Comirnaty EPAR.
  96. ↑ Comirnaty.
  97. ↑ Status på koronavaksiner under godkjenning per 21.12.20 (in nb-NO).
  98. ↑ COVID-19: Bóluefninu Comirnaty frá BioNTech/Pfizer hefur verið veitt skilyrt íslenskt markaðsleyfi (in is).
  99. ↑ ၉၉.၀ ၉၉.၁ Første vaccine mod COVID19 godkendt i EU (in da-DK).
  100. ↑ "Serbia leads region in expecting COVID-19 vaccines within days"၊ BalkanInsight၊ 21 December 2020။ 26 December 2020 တင်နိဿဲဏအ် စၟဳစၟတ်တုဲ။ 
  101. ↑ "First shipment of Pfizer-BioNTech vaccine arrives in Serbia"၊ Serbian government website၊ 22 December 2020။ 26 December 2020 တင်နိဿဲဏအ် စၟဳစၟတ်တုဲ။ 
  102. ↑ Lim၊ Ida။ "Khairy: Malaysia can use Pfizer’s Covid-19 vaccine now as conditional registration granted"၊ Malay Mail၊ 2021-01-08။ 
  103. ↑ A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19. United States National Library of Medicine (14 July 2020).
  104. ↑ "COVID-19 vaccine candidate heads to widespread testing in U.S."၊ NPR၊ 27 July 2020။ 
  105. ↑ Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine (15 November 2020).
  106. ↑ "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine" (December 2020). New England Journal of Medicine. doi:10.1056/NEJMoa2035389. PMID 33378609. 
  107. ↑ Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19).
  108. ↑ Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older.
  109. ↑ "Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination" (3 December 2020). New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejmc2032195. ISSN 0028-4793. PMID 33270381. 
  110. ↑ "An mRNA Vaccine against SARS-CoV-2 – Preliminary Report" (July 2020). New England Journal of Medicine 383 (20): 1920–1931. doi:10.1056/NEJMoa2022483. PMID 32663912. 
  111. ↑ "An mRNA Vaccine against SARS-CoV-2 – Preliminary Report Supplementary appendix" (July 2020). New England Journal of Medicine. doi:10.1056/NEJMoa2022483. PMID 32663912. 
  112. ↑ Regulatory Decision Summary – Moderna COVID-19 Vaccine – Health Canada. Health Canada, Government of Canada (23 December 2020).
  113. ↑ Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel. modernatx.com (4 January 2021).
  114. ↑ Information for Healthcare Professionals on COVID-19 Vaccine Moderna (8 January 2021).
  115. ↑ Conditions of Authorisation for COVID-19 Vaccine Moderna (8 January 2021).
  116. ↑ Script error: The module returned a nil value. It is supposed to return an export table.
  117. ↑ Script error: The module returned a nil value. It is supposed to return an export table.
  118. ↑ Status på koronavaksiner under godkjenning per 6. januar 2021 (in nb-NO).
  119. ↑ COVID-19: Bóluefninu COVID-19 Vaccine Moderna frá hefur verið veitt skilyrt íslenskt markaðsleyfi (in is).
  120. ↑ ၁၂၀.၀ ၁၂၀.၁ Endnu en vaccine mod COVID-19 er godkendt af EU-Kommissionen (in da-DK).
  121. ↑ "Swissmedic erteilt Zulassung für Moderna-Impfstoff in der Schweiz"၊ SRF၊ 2020-01-12။ 2020-01-12 တင်နိဿဲဏအ် စၟဳစၟတ်တုဲ။ 
  122. ↑ Script error: The module returned a nil value. It is supposed to return an export table.
  123. ↑ Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19.
  124. ↑ "Клинические исследования вакцины "Спутник V" в Беларуси начались раньше" (in ru)၊ BELTA၊ 29 September 2020။ 
  125. ↑ "Sputnik-V from Russia arrives in India for clinal trials"၊ Hindustan Times၊ 1 December 2020။ 
  126. ↑ "Clinical trial: 17 volunteers given Russia's Sputnik V Covid-19 vaccine in Pune"၊ The Indian Express၊ 6 December 2020။ 
  127. ↑ "Sputnik V's Clinical Trials in Venezuela: What We Do and Do Not Know"၊ Pulitzer Center၊ 5 November 2020။ 
  128. ↑ "UAE begins trials of Russia’s Sputnik V Covid-19 vaccine"၊ ClinicalTrials၊ 8 January 2021။ 
  129. ↑ ၁၂၉.၀ ၁၂၉.၁ "Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia" (2020). The Lancet 396 (10255): 887–97. doi:10.1016/s0140-6736(20)31866-3. ISSN 0140-6736. PMID 32896291. 
  130. ↑ "The Russian vaccine for COVID-19" (November 2020). The Lancet. Respiratory Medicine 8 (11): e85–e86. doi:10.1016/S2213-2600(20)30402-1. PMID 32896274. 
  131. ↑ "Belarus registers Sputnik V vaccine, in first outside Russia - RDIF"၊ Reuters၊ 21 December 2020။ 
  132. ↑ "Argentina has registered the Sputnik V vaccine based on Russian clinical trial data"၊ sputnikvaccine.com။ 
  133. ↑ "Ministerio de Salud de Bolivia - Bolivia y Rusia firman contrato para adquirir 5,2 millones de dosis de la vacuna Sputnik-V contra la COVID-19"၊ www.minsalud.gob.bo။ 
  134. ↑ "Venezuela firma contrato para la adquisición de la vacuna rusa Sputnik V" (in es)၊ Reuters၊ 29 December 2020။ 
  135. ↑ "Agencija odobrila uvoz ruske vakcine Sputnjik V u Srbiju" (in sr-RS)၊ N1၊ 31 December 2020။ 
  136. ↑ "Guinea Begins Administering Russia's Sputnik V Covid-19 Vaccine" (in en)၊ africanews.၊ 31 December 2020။ 
  137. ↑ "Covid19: National Pharmaceuticals Agency registers Sputnik V vaccine" (in en)၊ Algeria Press service၊ 10 January 2021။ 
  138. ↑ "Palestine has become the first country in the Middle East to register Sputnik V vaccine" (in en)၊ RFID၊ 11 January 2021။ 
  139. ↑ Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu). United States National Library of Medicine (12 May 2020).
  140. ↑ Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV). United States National Library of Medicine (2 July 2020).
  141. ↑ "A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia" (10 August 2020). Registri Penyakit Indonesia. 
  142. ↑ Turkish official says CoronaVac vaccine 91.25% effective. ABC News.
  143. ↑ Sinovac’s Covid-19 Vaccine Is 78% Effective in Brazil Late-Stage Trials. Wall Street Journal (7 January 2021).
  144. ↑ "Eficaz em prevenir doença grave e morte por covid, Coronavac deve ter impacto em frear pandemia" (in Portuguese)၊ 2021-01-07။ 2021-01-07 တင်နိဿဲဏအ် စၟဳစၟတ်တုဲ။ 
  145. ↑ ၁၄၅.၀ ၁၄၅.၁ Soeriaatmadja၊ Wahyudi။ "Indonesia grants emergency use approval to Sinovac’s vaccine, local trials show 65% efficacy"၊ The Straits Times၊ 2021-01-11။ 2021-01-11 တင်နိဿဲဏအ် စၟဳစၟတ်တုဲ။ 
  146. ↑ CoronaVac’s Overall Efficacy in Brazil Measured at 50.4%. bloomberg.com.
  147. ↑ Tests show coronavirus vaccine by China's Sinovac is safe, says Brazil's Butantan Institute.
  148. ↑ Chile initiates clinical study for COVID-19 vaccine.
  149. ↑ Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated (8 October 2020).
  150. ↑ "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial" (November 2020). The Lancet Infectious Diseases 0. doi:10.1016/S1473-3099(20)30843-4. PMID 33217362. 
  151. ↑ Wu၊ Huizhong။ "China prepares large-scale rollout of domestically-produced coronavirus vaccines"၊ The Globe and Mail၊ 6 December 2020။ 
  152. ↑ Bolívia autoriza uso de vacinas Sputnik V e CoronaVac contra covid-19 (in pt-br).
  153. ↑ "BPOM Grants Emergency Use Authorization for Sinovac Vaccine"၊ Tempo၊ 2021-01-11။ 2021-01-11 တင်နိဿဲဏအ် စၟဳစၟတ်တုဲ။ 
  154. ↑ "Turkey to begin COVID-19 vaccine jabs by this weekend"၊ Anadolu၊ 2021-01-11။ 2021-01-11 တင်နိဿဲဏအ် စၟဳစၟတ်တုဲ။ 
  155. ↑ "AstraZeneca & Serum Institute of India sign licensing deal for 1 million doses of Oxford vaccine"၊ The Economic Times။ 
  156. ↑ "Covid-19 vaccine: Serum Institute signs up for 100 million doses of vaccines for India, low and middle-income countries"၊ The Financial Express၊ 7 August 2020။ 
  157. ↑ "The world's hopes for a coronavirus vaccine may run in these health care workers' veins"၊ São Paulo: CNN၊ 27 July 2020။ 
  158. ↑ Investigating a Vaccine Against COVID-19. United States National Library of Medicine (26 May 2020).
  159. ↑ A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19. European Union (21 April 2020).
  160. ↑ "A Phase III study to investigate a vaccine against COVID-19" (26 May 2020). doi:10.1186/ISRCTN89951424. ISRCTN89951424. 
  161. ↑ A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19. United States National Library of Medicine (12 May 2020).
  162. ↑ ၁၆၂.၀ ၁၆၂.၁ Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK – The Lancet.
  163. ↑ Trial of Oxford COVID-19 vaccine starts in Brazil. Jenner Institute.
  164. ↑ "Oxford COVID-19 vaccine final trials will be held in these 17 hospitals in India"၊ mint၊ 19 August 2020။ 
  165. ↑ "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial" (July 2020). Lancet 396 (10249): 467–78. doi:10.1016/S0140-6736(20)31604-4. PMID 32702298. 
  166. ↑ Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca (30 December 2020).
  167. ↑ Script error: The module returned a nil value. It is supposed to return an export table.
  168. ↑ Conditions of Authorisation for COVID-19 Vaccine AstraZeneca (30 December 2020).
  169. ↑ Argentine regulator approves AstraZeneca/Oxford COVID-19 vaccine. Reuters (30 December 2020).
  170. ↑ ၁၇၀.၀ ၁၇၀.၁ "India Approves Oxford-AstraZeneca Covid-19 Vaccine and 1 Other"၊ 3 January 2021။ 
  171. ↑ "El Salvador greenlights AstraZeneca, Oxford University COVID-19 vaccine"၊ Reuters၊ 30 December 2020။ 
  172. ↑ "La República Dominicana aprueba la vacuna de AstraZeneca contra la covid-19" (in es)၊ Agencia EFE၊ 31 December 2020။ 
  173. ↑ Sanitarios, Comisión Federal para la Protección contra Riesgos. AUTORIZACIÓN PARA USO DE EMERGENCIA A VACUNA ASTRAZENECA COVID-19 (in es).
  174. ↑ Oxford University-Astrazeneca vaccine: Bangladesh okays it for emergency use (in en).
  175. ↑ Bangladesh approves Oxford-AstraZeneca COVID-19 vaccine (in en).
  176. ↑ "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)" (18 July 2020). Chinese Clinical Trial Registry. 
  177. ↑ UAE: Ministry of Health announces 86 per cent vaccine efficacy. Gulf News.
  178. ↑ "A Chinese Covid-19 Vaccine Has Proved Effective, Its Maker Says"၊ The New York Times၊ 2020-12-30။ 
  179. ↑ A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above.
  180. ↑ Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19).
  181. ↑ A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells). Chinese Clinical Trial Register (ChiCTR).
  182. ↑ Bahrain allows Sinopharm COVID-19 vaccine candidate use in frontline workers. MSN.
  183. ↑ "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials" (13 August 2020). JAMA 324 (10): 951–960. doi:10.1001/jama.2020.15543. PMID 32789505. 
  184. ↑ http://xinhuanet.com/english/2021-01/03/c_139637781.htm
  185. ↑ First batch of Chinese Sinopharm vaccine arrives in Jordan (in en). Roya News.
  186. ↑ "Chinese Covid-19 Vaccine Gets Key Push, but Doubts Swirl"၊ The New York Times၊ 9 December 2020။ 
  187. ↑ Coronavirus: UAE authorises emergency use of vaccine for frontline workers.
  188. ↑ An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers.
  189. ↑ Bharat Biotech Recruits 23,000 Volunteers For Covaxin's Phase 3 Clinical Trial (28 December 2020).
  190. ↑ Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers.
  191. ↑ ၁၉၁.၀ ၁၉၁.၁ ၁၉၁.၂ ၁၉၁.၃ ၁၉၁.၄ ၁၉၁.၅ ၁၉၁.၆ ၁၉၁.၇ Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 (EpiVacCorona). United States National Library of Medicine (22 September 2020). နိဿဲ ဗၠေတ် - Invalid <ref> tag; name "NCT04527575" defined multiple times with different content
  192. ↑ "Russian EpiVacCorona Vaccine Has No Adverse Effects" (in en)၊ OREANDA-NEWS၊ 13 January 2021။ 
  193. ↑ "Over 1,400 volunteers get Russia's first EpiVacCorona vaccine jab" (in en)၊ TASS၊ 15 December 2020။ 
  194. ↑ О регистрации вакцины ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора «ЭпиВакКорона» (in ru) (14 October 2020).
  195. ↑ Russia’s EpiVacCorona vaccine post-registration trials started (in en). The Pharma Letter (18 November 2020).
  196. ↑ Así funcionan las cuatro vacunas que se probarán en Chile. La Tercera (15 November 2020).
  197. ↑ CanSino Biologics delivers COVID-19 vaccine to Mexico for late-stage trial. Reuters (3 November 2020).
  198. ↑ China's CanSino trials Covid-19 vaccine in 'high disease burden' nations. South China Morning Post (28 October 2020).
  199. ↑ ၁၉၉.၀ ၁၉၉.၁ Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19. United States National Library of Medicine (13 November 2020).
  200. ↑ CanSino to start Phase III trial of COVID-19 vaccine in Saudi. Reuters (9 August 2020).
  201. ↑ Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above.
  202. ↑ "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial" (July 2020). Lancet 396 (10249): 479–88. doi:10.1016/s0140-6736(20)31605-6. ISSN 0140-6736. PMID 32702299. 
  203. ↑ CanSino's COVID-19 vaccine approved for military use in China.
  204. ↑ "More Than 2.7 Million People Have Gotten Vaccines: Covid-19 Tracker"၊ Bloomberg L.P.။ 
  205. ↑ ၂၀၅.၀ ၂၀၅.၁ နိဿဲ ဗၠေတ် - Invalid <ref> tag; no text was provided for refs named london
  206. ↑ COVID-19 vaccine tracker (Choose vaccines tab, apply filters to view select data). Milken Institute (8 December 2020).
  207. ↑ နိဿဲ ဗၠေတ် - Invalid <ref> tag; no text was provided for refs named who-tracker
  208. ↑ A Study of Ad26.COV2.S in Adults (4 August 2020).
  209. ↑ A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants. US National Library of Medicine.
  210. ↑ "Johnson & Johnson pauses its coronavirus vaccine trial because of a volunteer's 'unexplained illness.'"၊ 13 October 2020။ 
  211. ↑ "Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&J Resuming"၊ The Wall Street Journal၊ 23 October 2020။ 
  212. ↑ Johnson၊ Carolyn Y.။ "Johnson & Johnson, AstraZeneca coronavirus vaccine trials set to resume"၊ The Washington Post၊ 24 October 2020။ 
  213. ↑ နိဿဲ ဗၠေတ် - Invalid <ref> tag; no text was provided for refs named EU Ad26.COV2.S rolling review
  214. ↑ "Johnson & Johnson the first to apply for Covid-19 vaccine registration as South Africa starts review process" MSN. 17 December 2020.
  215. ↑ Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant. United States National Library of Medicine (30 April 2020).
  216. ↑ A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom.
  217. ↑ "Three Kolkata institutes queue up for corona vaccine trials | Kolkata News"၊ The Times of India၊ 23 November 2020။ 
  218. ↑ A Study Looking at the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults at Risk for SARS-CoV-2 - Full Text View - ClinicalTrials.gov (in en).
  219. ↑ "Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine" (September 2020). The New England Journal of Medicine 383 (24): 2320–2332. doi:10.1056/NEJMoa2026920. PMID 32877576. 
  220. ↑ Ebrard၊ Marcelo။ "Informe de avance sobre vacunas al 15 de diciembre de 2020."။ ထာမ်ပလိက်:Primary source inline
  221. ↑ An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers.
  222. ↑ Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers.
  223. ↑ "Bharat Biotech Seeks Emergency Use Approval For Covaxin"၊ NDTV.com၊ 8 December 2020။ 
  224. ↑ GSK, Medicago launch phase 2/3 clinical trials of plant-derived COVID-19 vaccine (13 November 2020).
  225. ↑ Chander၊ Vishwadha။ "Canada's Medicago begins human trials of plant-based COVID-19 vaccine"၊ National Post၊ 14 July 2020။ 
  226. ↑ Medicago (18 November 2020). "Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years of Age or Older". 
  227. ↑ "A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19 - Full Text View - ClinicalTrials.gov" . Clinicaltrials.gov. 
  228. ↑ Fifth Chinese Covid-19 vaccine candidate ready to enter phase 3 trials. South China Morning Post (20 November 2020).
  229. ↑ MYEG to conduct phase 3 clinical trial for China's Covid-19 vaccine in Msia | New Straits Times. New Straits Times (7 December 2020).
  230. ↑ A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years. United States National Library of Medicine (10 July 2020).
  231. ↑ COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older (19 November 2020).
  232. ↑ A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults (26 June 2020).
  233. ↑ A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults (17 August 2020).
  234. ↑ ၂၃၄.၀ ၂၃၄.၁ A Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults. United States National Library of Medicine (1 November 2020).
  235. ↑ As Israel goes vaccine-wild, will the homegrown version lose its shot? (29 December 2020).
  236. ↑ Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers. United States National Library of Medicine (7 April 2020).
  237. ↑ IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea. International Vaccine Institute (16 April 2020).
  238. ↑ Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19. United States National Library of Medicine (2 June 2020).
  239. ↑ Study of COVID-19 DNA Vaccine (AG0301-COVID19). United States National Library of Medicine (9 July 2020).
  240. ↑ About AnGes – Introduction.
  241. ↑ CTI and Arcturus Therapeutics Announce Initiation of Dosing of COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study. UK BioIndustry Association (13 August 2020).
  242. ↑ Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects.
  243. ↑ Safety and Immunity of Covid-19 aAPC Vaccine. United States National Library of Medicine (9 March 2020).
  244. ↑ ၂၄၄.၀ ၂၄၄.၁ About Us. Shenzhen Genoimmune Medical Institute.
  245. ↑ Immunity and Safety of Covid-19 Synthetic Minigene Vaccine. United States National Library of Medicine (19 February 2020).
  246. ↑ "Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women" (22 May 2020). doi:10.1186/ISRCTN17072692. ISRCTN17072692. 
  247. ↑ A prospective, randomized, adaptive, phase I/II clinical study to evaluate the safety and immunogenicity of Novel Corona Virus −2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects. Clinical Trials Registry India (15 December 2020).
  248. ↑ "COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies" (24 November 2020). European Journal of Pharmacology 892: 173751. doi:10.1016/j.ejphar.2020.173751. ISSN 1879-0712. PMID 33245898. PMC:7685956. 
  249. ↑ Thacker၊ Teena။ "Zydus Cadila to test ZyCoV-D on 30,000 patients in Phase-3 trials"၊ The Economic Times။ 
  250. ↑ Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults. United States National Library of Medicine (24 June 2020).
  251. ↑ "S. Korea's Genexine begins human trial of coronavirus vaccine"၊ Reuters၊ 19 June 2020။ 
  252. ↑ "Genexine consortium's Covid-19 vaccine acquires approval for clinical trails in Korea"၊ 11 June 2020။ 
  253. ↑ SCB-2019 as COVID-19 Vaccine. United States National Library of Medicine (28 May 2020).
  254. ↑ Clover Biopharmaceuticals starts Phase I Covid-19 vaccine trial. Clinical Trials Arena (20 June 2020).
  255. ↑ About Us.
  256. ↑ Monovalent Recombinant COVID19 Vaccine (COVAX19). United States National Library of Medicine (1 July 2020).
  257. ↑ Vaxine.
  258. ↑ A Phase I clinical trial to evaluate the safety, tolerance and preliminary immunogenicity of different doses of a SARS-CoV-2 mRNA vaccine in population aged 18–59 years and 60 years and above (24 June 2020).
  259. ↑ Company introduction.
  260. ↑ A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults. United States National Library of Medicine (3 August 2020).
  261. ↑ UQ-CSL V451 Vaccine.

Footnotes[ပလေဝ်ဒါန် | ပလေဝ်ဒါန် တမ်ကၞက်]

ဆက်ဗှ်[ပလေဝ်ဒါန် | ပလေဝ်ဒါန် တမ်ကၞက်]

လေန် မ္ၚး[ပလေဝ်ဒါန် | ပလေဝ်ဒါန် တမ်ကၞက်]


နိဿဲ ဗၠေတ် - <ref> tags exist for a group named "lower-alpha", but no corresponding <references group="lower-alpha"/> tag was found

ကလေင်သီကေတ်လဝ် နူ "https://mnw.wikipedia.org/w/index.php?title=ဝက်သိန်_ကဝ်ဝိဒ်-၁၉&oldid=25918"